<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006418.pub3" GROUP_ID="INFECTN" ID="024006032117211881" MERGED_FROM="" MODIFIED="2017-08-23 10:47:48 +0100" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2017-08-18 14:53:50 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-04-05 12:19:30 +0100" MODIFIED_BY="[Empty name]">Isoniazid for preventing tuberculosis in HIV-infected children</TITLE>
<CONTACT>
<PERSON ID="98925488226530131232120516173728" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Moleen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zunza</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>moleenz@sun.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences</DEPARTMENT>
<ORGANISATION>Stellenbosch University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>0219389512</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-08-18 14:13:32 +0100" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="98925488226530131232120516173728" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Moleen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zunza</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>moleenz@sun.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences</DEPARTMENT>
<ORGANISATION>Stellenbosch University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>0219389512</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2D7AB2B682E26AA20112E9E6E62676F3" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Diane</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Gray</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>diane.gray@uct.ac.za</EMAIL_1>
<EMAIL_2>graysteven@mweb.co.za</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatrics and Child Health</DEPARTMENT>
<ORGANISATION>Red Cross War Memorial Children's Hospital and University of Cape Town</ORGANISATION>
<ADDRESS_1>Klipfontein Road</ADDRESS_1>
<ADDRESS_2>Rondebosch</ADDRESS_2>
<CITY>Cape Town</CITY>
<ZIP>7700</ZIP>
<REGION>Western Cape</REGION>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 658 5517</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16810" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Taryn</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Young</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tyoung@sun.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences</DEPARTMENT>
<ORGANISATION>Stellenbosch University</ORGANISATION>
<ADDRESS_1>PO Box 241</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP>8000</ZIP>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 938 9886</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2D7C197B82E26AA20112E9E6F926DEA4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Mark</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cotton</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>mcot@sun.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Children's Infectious Diseases Clinical Research</DEPARTMENT>
<ORGANISATION>Tygerberg Children's Hospital</ORGANISATION>
<ADDRESS_1>J8 Tygerberg Children's Hospital</ADDRESS_1>
<ADDRESS_2>Francie van Zijl Drive</ADDRESS_2>
<CITY>Tygerberg</CITY>
<ZIP>7505</ZIP>
<REGION>Cape Provice</REGION>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 938 4219</PHONE_1>
<PHONE_2/>
<FAX_1>+27 21 938 4153</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="20026" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Heather</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Zar</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>heather.zar@uct.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatrics and Child Health</DEPARTMENT>
<ORGANISATION>Red Cross Children's Hospital and MRC Unit on Child and Adolescent Health, University of Cape Town</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP>7700</ZIP>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 658 5350</PHONE_1>
<PHONE_2/>
<FAX_1>+27 21 689 1287</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-03-02 10:39:26 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="17" MONTH="2" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="2" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="2" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-18 14:53:50 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-08-18 14:53:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="8" YEAR="2017"/>
<DESCRIPTION>
<P>Search updated and new studies added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-08-18 14:53:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="2" YEAR="2017"/>
<DESCRIPTION>
<P>Search updated and new studies added. A new author joined the team.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-05-22 19:29:29 +0100" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-05-22 19:29:29 +0100" MODIFIED_BY="Tara Horvath">
<DATE DAY="24" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Added author whose name had inadvertently been omitted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-06-30 11:51:18 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2017-06-30 11:51:18 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2017-06-30 11:51:18 +0100" MODIFIED_BY="[Empty name]">
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2017-06-30 11:51:09 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>HIV/AIDS mentoring programme, South African Cochrane Centre</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Cochrane Child Health Field Bursary</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2017-06-30 11:51:09 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department for International Development, UK. Research Programme Grant</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Grant: 5242</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-08-17 10:45:30 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-08-17 10:44:14 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-08-17 10:42:45 +0100" MODIFIED_BY="[Empty name]">Isoniazid prophylaxis for preventing active tuberculosis and death in HIV-positive children</TITLE>
<SUMMARY_BODY MODIFIED="2017-08-17 10:44:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>What was the aim of this review? </B>
</P>
<P>To summarise the effects of isoniazid prophylaxis on TB, death, and adverse effects in HIV-positive children.</P>
<P>
<B>Key messages</B>
</P>
<P>In areas of high tuberculosis endemicity, isoniazid prophylaxis prevents active TB and death in HIV-positive children who are not on ART.</P>
<P>We conducted a review to assess the effect of TB medication on active TB or death and its safety in HIV-positive children.</P>
<P>
<B>What was studied in the review? </B>
</P>
<P>TB is a common cause of severe lung disease and death in HIV-positive children. Childhood TB is common in poor countries, especially those with a coexisting burden of HIV/AIDS disease. HIV-positive children have a higher risk of developing TB than HIV-negative children. Isoniazid prevents TB in HIV-positive adults and is currently used in children who are at high risk of developing TB disease after exposure to someone with TB. However, there is limited information on the effect of isoniazid medication in reducing active TB or death if given to HIV-positive children without known TB contact.</P>
<P>We searched for studies up to 17 February 2017, and found three studies published between 2007 and 2014 that addressed the effect of isoniazid medication compared to no medication on active TB and death in 991 HIV-positive children, below the age of 13 years. Most of the children were on antiretroviral therapy (ART) and the studies were conducted in South Africa and Botswana. The median length of follow-up ranged from 5.7 to 34 months.</P>
<P>
<B>What are the main results of the review?</B>
</P>
<P>In HIV-positive children not taking ART, isoniazid medication reduced the number of children developing active TB by 69% (<I>low certainty evidence</I>), and death by 54% (<I>low certainty evidence</I>).</P>
<P>One trial was conducted in HIV-positive children taking ART, and this did not detect any benefit or harm of isoniazid (<I>very low certainty evidence)</I>.</P>
<P>The number of children with adverse effects were similar in children receiving isoniazid medication as the control group in both children on ART and not on ART.</P>
<P>
<B>How up to date is the review?</B>
</P>
<P>The review authors searched for studies published up to February 2017.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-08-17 10:45:19 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-08-17 10:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Tuberculosis (TB) is an important cause of illness and death in HIV-positive children living in areas of high TB prevalence. We know that isoniazid prophylaxis prevents TB in HIV-negative children following TB exposure, but there is uncertainty related to its role in TB preventive treatment in HIV-positive children.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-08-17 10:45:19 +0100" MODIFIED_BY="[Empty name]">
<P>To summarise the effects of TB preventive treatment versus placebo in HIV-positive children with no known TB contact on active TB, death, and reported adverse events.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-07-18 15:26:09 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE/PubMed, Embase and two trial registers up to February 2017.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-06-30 13:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials of HIV-positive children with and without known TB exposure, randomized to receive TB preventive treatment or placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-08-17 10:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently used the study selection criteria, assessed risk of bias, and extracted data. We assessed effects using risk, incidence rate and hazard ratios and assessed the certainty of evidence using GRADE.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-07-17 12:05:10 +0100" MODIFIED_BY="[Empty name]">
<P>We included three trials, involving 991 participants, below the age of 13 years, from South Africa and Botswana. Children were randomized to isoniazid prophylaxis or placebo, given daily or three times weekly. The median length of follow-up ranged from 5.7 to 34 months; some were on antiretroviral therapy (ART).</P>
<P>In HIV-positive children not on ART, isoniazid prophylaxis may reduce the risk of active TB (hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 participants, <I>low certainty evidence</I>), and death (HR 0.46, 95% CI 0.22 to 0.95; 1 trial, 240 participants, <I>low certainty evidence</I>). One trial (182 participants) reported number of children with laboratory adverse events, which was similar between the isoniazid prophylaxis and placebo groups. No clinical adverse events were reported.</P>
<P>In HIV-positive children on ART, we do not know if isoniazid prophylaxis reduces the risk of active TB (risk ratio (RR) 0.76, 95% CI 0.50 to 1.14; 3 trials, 737 participants, <I>very low certainty evidence</I>) or death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, <I>very low certainty evidence</I>). Two trials (714 participants) reported number of clinical adverse events and three trials (795 participants) reported number of laboratory adverse events; for both categories, the number of adverse events were similar between the isoniazid prophylaxis and placebo groups.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-08-17 10:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Isoniazid prophylaxis given to all children diagnosed with HIV may reduce the risk of active TB and death in HIV-positive children not on ART in studies from Africa. For children on ART, no clear benefit was detected. .</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-08-17 10:45:30 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-08-08 14:32:05 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-07-12 10:43:45 +0100" MODIFIED_BY="[Empty name]">
<P>Tuberculosis (TB) is an important cause of childhood morbidity and death especially in HIV-positive children (<LINK REF="REF-Kochi-1991" TYPE="REFERENCE">Kochi 1991</LINK>; <LINK REF="REF-Donald-2002" TYPE="REFERENCE">Donald 2002</LINK>). Infection is caused by <I>Mycobacterium tuberculosis</I> and most commonly results in acute and chronic respiratory disease (<LINK REF="REF-Foster-2003" TYPE="REFERENCE">Foster 2003</LINK>). In 1994, the incidence of childhood TB increased in low- and middle-income countries (<LINK REF="REF-Nelson-2004" TYPE="REFERENCE">Nelson 2004</LINK>). This resurgence was partly attributed to the coexisting burden of HIV disease (<LINK REF="REF-WHO-2012" TYPE="REFERENCE">WHO 2012</LINK>), which is most pronounced in sub-Saharan Africa. At the end of 2012, an estimated 3.3 million children under 15 years of age, were living with HIV (<LINK REF="REF-UNAIDS_x002f_WHO-2013" TYPE="REFERENCE">UNAIDS/WHO 2013</LINK>), and 260,000 new HIV infections in children in low- and middle-income countries were reported the same year (<LINK REF="REF-UNAIDS_x002f_WHO-2013" TYPE="REFERENCE">UNAIDS/WHO 2013</LINK>). The World Health Organization (WHO) estimates that, of the 8.7 million incident cases of TB in 2011, approximately 500,000 occurred in children under 15 years of age (<LINK REF="REF-WHO-2012" TYPE="REFERENCE">WHO 2012</LINK>). However, the burden of childhood TB disease is not as well documented as in adults, partly because of the difficulty of confirming the diagnosis.</P>
<P>Dual infection with TB has an important impact on HIV disease. TB accelerates the progression of HIV disease by increasing viral replication (<LINK REF="REF-Whalen-1995" TYPE="REFERENCE">Whalen 1995</LINK>; <LINK REF="REF-Goletti-1996" TYPE="REFERENCE">Goletti 1996</LINK>). TB is a common cause of acute pneumonia in African HIV-positive children (<LINK REF="REF-Zar-2001" TYPE="REFERENCE">Zar 2001</LINK>; <LINK REF="REF-Jeena-2002" TYPE="REFERENCE">Jeena 2002</LINK>), and may lead to chronic lung disease, including bronchiectasis (<LINK REF="REF-Ikeogu-1997" TYPE="REFERENCE">Ikeogu 1997</LINK>; <LINK REF="REF-Jeena-1998" TYPE="REFERENCE">Jeena 1998</LINK>). TB is a common cause of death in HIV-positive children (<LINK REF="REF-Ikeogu-1997" TYPE="REFERENCE">Ikeogu 1997</LINK>; <LINK REF="REF-Chintu-2005" TYPE="REFERENCE">Chintu 2005</LINK>). Antimycobacterial drugs, such as rifampicin, have deleterious drug interactions with antiretroviral therapy (ART), complicating treatment. Rifampicin, an inducer of cytochrome P450 CYP3A, decreases the concentration of both the protease inhibitors and non-nucleoside reverse transcriptase inhibitors, leading to sub-therapeutic levels, and increasing the risk for inadequate viral suppression and consequent drug resistance (<LINK REF="REF-Ren-2008" TYPE="REFERENCE">Ren 2008</LINK>; <LINK REF="REF-Ren-2009" TYPE="REFERENCE">Ren 2009</LINK>). The large pill burden of two multiple drug regimens increases the risk of adverse events, such as liver toxicity and the likelihood of poorer adherence (<LINK REF="REF-Burman-2005" TYPE="REFERENCE">Burman 2005</LINK>).</P>
<P>Conversely, HIV infection has an impact on TB disease. HIV-positive children have a higher risk of developing primary TB than HIV-negative children (<LINK REF="REF-Mukadi-1997" TYPE="REFERENCE">Mukadi 1997</LINK>; <LINK REF="REF-Hesseling-2009" TYPE="REFERENCE">Hesseling 2009</LINK>). The diagnosis of TB is more difficult in HIV-positive children, as other infections or HIV disease may mimic TB. Furthermore, tuberculin skin testing is less sensitive due to immunosuppression, and chest radiography is less specific (<LINK REF="REF-Berggren-Palme-2002" TYPE="REFERENCE">Berggren Palme 2002</LINK>; <LINK REF="REF-Chintu-2005" TYPE="REFERENCE">Chintu 2005</LINK>). The outcome of HIV-positive versus HIV-negative children with TB co-infection is poorer, with six-fold increased death in HIV-positive children not on ART (<LINK REF="REF-Berggren-Palme-2002" TYPE="REFERENCE">Berggren Palme 2002</LINK>; <LINK REF="REF-Hesseling-2005" TYPE="REFERENCE">Hesseling 2005</LINK>). The cure rate of TB in HIV-positive children not on ART is significantly lower than in HIV-negative children (<LINK REF="REF-Mukadi-1997" TYPE="REFERENCE">Mukadi 1997</LINK>; <LINK REF="REF-Berggren-Palme-2002" TYPE="REFERENCE">Berggren Palme 2002</LINK>), with a higher rate of recurrence (<LINK REF="REF-Schaaf-2005" TYPE="REFERENCE">Schaaf 2005</LINK>). HIV-positive children may therefore require a longer course of TB treatment (<LINK REF="REF-Perriens-1995" TYPE="REFERENCE">Perriens 1995</LINK>; <LINK REF="REF-Schaaf-1998" TYPE="REFERENCE">Schaaf 1998</LINK>). HIV-positive children, stable on ART, are less likely to develop TB disease and have a better outcome than those not on ART (<LINK REF="REF-Walters-2008" TYPE="REFERENCE">Walters 2008</LINK>; <LINK REF="REF-Edmonds-2009" TYPE="REFERENCE">Edmonds 2009</LINK>; <LINK REF="REF-Martinson-2009" TYPE="REFERENCE">Martinson 2009</LINK>). However, the initiation of ART in the setting of TB co-infection can lead to a paradoxical worsening of TB from the 'immune reconstitution syndrome' (<LINK REF="REF-Narita-1998" TYPE="REFERENCE">Narita 1998</LINK>; <LINK REF="REF-Puthanakit-2006" TYPE="REFERENCE">Puthanakit 2006</LINK>; <LINK REF="REF-Zampoli-2007" TYPE="REFERENCE">Zampoli 2007</LINK>; <LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>). Moreover, the risk of TB in HIV-positive children on ART is still higher than that of HIV-negative children (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-07-02 09:27:17 +0100" MODIFIED_BY="[Empty name]">
<P>Isoniazid preventive treatment (IPT) is a secondary prevention strategy, whereby isoniazid prevents progression of latent TB to active TB in those at high-risk of developing active TB (<LINK REF="REF-Cohen-2006" TYPE="REFERENCE">Cohen 2006</LINK>). The WHO currently recommends that HIV/AIDS programmes include IPT as part of their package of care for HIV-positive people. Current guidelines recommend six months of IPT for HIV-positive children aged one year and above, without TB disease, even in the absence of a known TB contact; IPT for up to 3 years of use is recommended in HIV-positive adolescents or adults (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>; <LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). </P>
</INTERVENTION>
<THEORY MODIFIED="2017-08-08 14:32:05 +0100" MODIFIED_BY="[Empty name]">
<P>Preventing TB infection and disease in HIV-positive children is potentially an important public health intervention. Isoniazid has been used successfully as preventive treatment in HIV-negative children following TB exposure (<LINK REF="REF-Smieja-1999" TYPE="REFERENCE">Smieja 1999</LINK>), and in HIV-infected adults with a positive tuberculin skin test (<LINK REF="REF-Akolo-2010" TYPE="REFERENCE">Akolo 2010</LINK>), where treatment reduced TB disease by 62%.This benefit was found for all preventive drug regimens: isoniazid alone, isoniazid with rifampicin, rifampicin with pyrazinamide and isoniazid, rifampicin and pyrazinamide. No reduction in death was found. Isoniazid offers a further 40% reduction in active TB among HIV-positive adults on ART (<LINK REF="REF-Rangaka-2014" TYPE="REFERENCE">Rangaka 2014</LINK>). Studies showed that IPT reduces active TB at the community and population level (<LINK REF="REF-Grant-2005" TYPE="REFERENCE">Grant 2005</LINK> ). However, the strategy may be compromised by low adherence over the many months necessary to complete a single course of IPT, a problem worsened in HIV-TB co-infected individuals for whom IPT durations are prolonged. In contrast to adults, preventive treatment in children is aimed at preventing primary infection rather than reactivation of disease (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). In settings of high TB prevalence, the rate of TB re-infection is high (<LINK REF="REF-Verver-2005" TYPE="REFERENCE">Verver 2005</LINK>), and short-course prophylaxis is potentially inadequate. Longer-term prophylaxis or repeat courses may be necessary. Preventive treatment can lead to adverse events, mostly liver toxicity, although this is uncommon and rarely requires cessation of antimycobacterial medication in HIV-positive children (<LINK REF="REF-Gray-2009a" TYPE="REFERENCE">Gray 2009a</LINK>; <LINK REF="REF-Donald-2000" TYPE="REFERENCE">Donald 2000</LINK>; <LINK REF="REF-Gray-2009a" TYPE="REFERENCE">Gray 2009a</LINK>; <LINK REF="STD-Le-Roux-2013" TYPE="STUDY">Le Roux 2013</LINK>).The benefits of isoniazid outweigh the risk of liver damage for HIV-infected people (<LINK REF="REF-Getahun-2010" TYPE="REFERENCE">Getahun 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-07-17 12:21:58 +0100" MODIFIED_BY="[Empty name]">
<P>In high-TB prevalence areas, TB preventive treatment may be effective in preventing infection and development of disease in HIV-positive children. The efficacy of preventive treatment may, however, be limited by adherence difficulties, adverse events, and cost implications. The true efficacy of TB preventive treatment in HIV-positive children must be clearly established and balanced against the occurrence of these events. We decided to undertake a Cochrane Review on the efficacy and safety of TB preventive treatment in HIV-positive children with prophylaxis started in all children diagnosed with HIV infection.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-08-17 10:45:30 +0100" MODIFIED_BY="[Empty name]">
<P>To summarise the effects of TB preventive treatment versus placebo in HIV-positive children with no known TB contact on active TB, death, and reported adverse events.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-08-08 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-08-08 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-06-26 14:06:51 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials (RCTs) that evaluated the efficacy of TB preventive treatment in participants randomly allocated to preventive treatment for TB and placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-06-30 20:02:05 +0100" MODIFIED_BY="[Empty name]">
<P>We included HIV-positive children, below 13 years, without TB disease currently (irrespective of prior history of TB treatment, infection or prophylaxis). We included children on antiretroviral therapy (ART). For studies that included eligible and non-eligible participants, we included only effect estimates of eligible participants.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-06-30 20:02:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Intervention group: any TB drug or drug combination.</LI>
<LI>Comparison group: inactive placebo.</LI>
</UL>
<P>We did not impose any restrictions on study interventions, such as dose, duration of treatment, timing of outcome measurement, or co-interventions.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-08-08 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-06-26 14:29:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Active TB</LI>
</UL>
<P>We defined definite TB by a microbiological or histological identification of <I>Mycobacterium tuberculosis.</I> We based the diagnosis of probable TB on a combination of typical clinical symptoms and signs, tuberculin skin testing, chest radiography, a history of close TB contact, and a documented response to antimycobacterial treatment.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-08-08 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death</LI>
<LI>Grade 3 or higher clinical adverse events</LI>
<UL>
<LI>Peripheral neuropathy (defined as sensory alteration or paraesthesia causing inability to perform usual social and functional activities or disabling sensory alteration or paraesthesia causing inability to perform age appropriate basic self-care functions) (<LINK REF="REF-NIAID-2014" TYPE="REFERENCE">NIAID 2014</LINK>)</LI>
<LI>Other clinical adverse events</LI>
</UL>
</UL>
<UL>
<LI>Grade 3 or higher laboratory adverse events</LI>
<UL>
<LI>Haematological abnormalities (defined as neutrophil count of 500/mm<SUP>3</SUP> to 749/mm<SUP>3</SUP> or &lt; 500/mm<SUP>3</SUP>; platelet count of 25,000 to 49,999/mm<SUP>3</SUP> or &lt; 25,000/mm<SUP>3</SUP>; haemoglobin of 6.5 g/dL to 7.5 g/dL or &lt; 6.5 g/dL) (<LINK REF="REF-NIAID-2014" TYPE="REFERENCE">NIAID 2014</LINK>)</LI>
</UL>
</UL>
<UL>
<UL>
<LI>Liver enzyme abnormalities (raised alanine aminotransferase and aspartate aminotransferase of 5.1 to 10 or &gt; 10, the upper limit of normal) (<LINK REF="REF-NIAID-2014" TYPE="REFERENCE">NIAID 2014</LINK>)</LI>
<LI>Other laboratory adverse events</LI>
</UL>
</UL>
<P>We graded adverse events according to the standardized paediatric AIDS clinical trial grading system of severity of adverse events (<LINK REF="REF-NIAID-2014" TYPE="REFERENCE">NIAID 2014</LINK>).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-07-11 19:19:16 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2017-07-11 19:19:16 +0100" MODIFIED_BY="[Empty name]">
<P>We searched:</P>
<UL>
<LI>MEDLINE/PubMed (1946 to 17 February 2017) <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>;</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library (17 February 2017) <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; and</LI>
<LI>Embase (1974 to 17 February 2017) <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</LI>
</UL>
<P>We also searched for ongoing RCTs of chemoprophylaxis in HIV-positive children in:</P>
<UL>
<LI>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<A HREF="http://www.who.int/ictrp/en/">www.who.int/ictrp</A>; to 17 February 2017); and</LI>
<LI>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">www.clinicaltrials.gov</A>; to 17 February 2017).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-07-02 09:34:55 +0100" MODIFIED_BY="[Empty name]">
<P>We handsearched reference lists of identified articles and review articles. We screened abstracts and proceedings of the International Union Against Tuberculosis and Lung Disease (IUATLD) World Congress, the American Thoracic Society International Congress, and the European Respiratory Society World Congress conferences. We contacted investigators of identified trials and other content experts to locate information on any further trials that may not have been included in the electronic databases or presented at conferences, to find out whether these were completed, ongoing, or published. We scrutinized non-Cochrane reviews for any additional relevant studies or unpublished data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-07-12 14:16:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2017-07-03 09:15:34 +0100" MODIFIED_BY="[Empty name]">
<P>MZ and TY scrutinized studies independently for eligibility. We retrieved the full text of relevant articles and independently examined them for eligibility. We included studies if they met the prespecified eligibility criteria. Authors assessing study eligibility were not blinded to the names of the trial investigators, their institutions, journals of publication or results of study. Reasons for excluding studies are summarized in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. We record the selection process in sufficient detail to complete a PRISMA flow diagram <LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-07-09 18:08:18 +0100" MODIFIED_BY="[Empty name]">
<P>MZ and a research assistant (OA) extracted the data. The following study characteristics and outcomes were independently extracted in duplicate, under the following subheadings:</P>
<UL>
<LI>Methods (study design, study duration, methodological quality).</LI>
<LI>Participants (inclusion and exclusion criteria, number of patients randomized, setting).</LI>
<LI>Interventions (allocated treatment and dosage regimen, treatment duration)</LI>
<LI>Outcomes (active TB, death, clinical and laboratory adverse events).</LI>
<LI>Study results (number of participants with event of interest and the total number in that study arm for dichotomous outcomes; number lost to follow-up, and how incomplete data were addressed)</LI>
</UL>
<P>Review authors who authored an included study did not participate in data extraction and assessment of risk of bias of included studies to maintain independence of the review. We summarized data in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-07-12 14:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>We used Cochrane's 'Risk of bias' tool to assess the included studies (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). MZ and OA independently assessed the methodological quality of the included studies. We assessed the following domains.</P>
<UL>
<LI>The adequacy of generation of allocation sequence and allocation concealment in preventing selection bias.</LI>
<LI>The presence or absence of blinding of the participant and personnel to reduce performance bias.</LI>
<LI>The method of outcome assessment: whether the same method of assessment was used in both groups and presence or absence of blinding of outcome assessor in the prevention of detection bias.</LI>
<LI>Attrition bias by looking at the percentage of participants included in final analyses and the description of those not included. We also assessed whether or not an intention-to-treat analysis was performed.</LI>
<LI>We compared protocols of included studies with published articles to assess for risk of selective reporting bias.</LI>
<LI>Other bias.</LI>
</UL>
<P>We assigned the following judgements for risk of bias for each domain: low risk, high risk, and unclear risk of bias. We resolved disagreements on eligibility and methodological quality of trials by discussion and by obtaining further information from trial authors. We summarized data in a 'Risk of bias' table and graph, which shows our judgements on risk of bias in each domain, for each study separately, and as a percentage across all included studies.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-07-09 18:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>For binary outcomes, we calculated risk ratios (RRs) and associated 95% confidence intervals (CIs). We assessed the effect of the intervention (isoniazid prophylaxis) compared to control (placebo) on the time to event (death and developing TB) with the hazard and incidence rate ratios (95% CI) presented in study reports.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2017-06-27 14:03:23 +0100" MODIFIED_BY="[Empty name]">
<P>Two included trials used an intention-to-treat analysis to address missing data from participant dropout and the attrition rate was low in the third trial. We contacted the primary author of one included study for missing summary statistics, however, the author did not respond.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-06-27 14:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>We used the Chi<SUP>2</SUP> test and I<SUP>2 </SUP>statistic to assess statistical heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). We considered statistical heterogeneity to be substantial when the Chi<SUP>2</SUP> test, which assesses if the observed differences in results are due to chance alone, had a P value of &lt; 0.10 and when the I<SUP>2 </SUP>statistic, describing the percentage of variability in effect estimates due to heterogeneity, was &gt; 50%.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-07-03 11:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>There were too few studies to enable investigation of publication bias using funnel plots.</P>
<P>
<B>Unit of analysis issues</B>
</P>
<P>All included trials followed a simple parallel group design, where children were individually randomized to either isoniazid prophylaxis or placebo group and a single measurement for each outcome (i.e. active TB or death) was collected and analyzed.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-07-09 18:09:19 +0100" MODIFIED_BY="[Empty name]">
<P>We used a fixed-effect meta-analysis incorporating the Mantel-Haenszel method for dichotomous outcomes and the inverse-variance method for time-to-event outcomes to pool results across studies with no significant heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). Where meta-analysis was inappropriate, we reported individual study results separately. We used Review Manager 5 for analysis (<LINK REF="REF-Review-Manager-2014" TYPE="REFERENCE">Review Manager 2014</LINK>). We stratified the analysis by whether the children were receiving ART or not.</P>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of overall certainty of evidence</HEADING>
<P>We used GRADE methodology to assess the overall certainty of evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). In evaluating the certainty of RCT evidence, we considered the following in whether to downgrade the certainty of evidence: methodological limitations, unexplained heterogeneity or inconsistency of study results, indirectness of evidence, imprecision of results, and risk for publication bias. We rated the certainty across studies as high, moderate, low, or very low.</P>
<P>We used GRADEpro software to create two 'Summary of findings' tables for the comparisons 'isoniazid prophylaxis compared to placebo for HIV-positive children not on ART' and 'isoniazid prophylaxis compared to placebo for HIV-positive children on ART' (<LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>). We included active TB and death outcomes in the 'Summary of findings' tables.</P>
<P>MZ and OA independently assessed the certainty of the evidence. We resolved disagreements on certainty ratings by discussion and provided justification for decisions to down- or upgrade the ratings using footnotes in the &#8216;Summary of findings&#8217; table and made comments to aid readers' understanding of the review, where necessary. We used plain language statements to report these findings in the review.<BR/>
</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-07-03 12:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>We considered a subgroup analysis based on background TB prevalence, but all studies were from high TB prevalence settings. We will consider subgroup analysis by background TB prevalence in subsequent review updates.</P>
<P>
<B>Sensitivity analysis</B>
</P>
<P>We could not perform sensitivity analysis due to limited number of trials included in the review.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-08-08 14:32:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-08-08 14:32:32 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-07-18 15:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>In the updated search (17 February 2017) we identified an additional two RCTs with 714 participants. We found no ongoing studies in the updated search (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-08-08 14:32:32 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Design</HEADING>
<P>We included three randomized controlled trials (RCTs) with a total of 991 participants in the review (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Two trials were conducted in South Africa (<LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>; <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>), and one was a multicentre trial that was conducted in South Africa and Botswana; however, enrolment in Botswana began shortly before the study was terminated (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>HIV-positive children in <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> and <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK> were older (median age 24.7 to 38 months) than those in <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK> (median age 3.2 months). <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> and <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK> included children who had a previous history of TB treatment or prophylaxis, 16% and 12%, respectively, compared to <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>, that excluded all children who had a history of TB or known exposure to a microbiologically confirmed case of TB. Compared to <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK> and <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>, children in <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> were severely malnourished at enrolment: median weight-for-age z-score &#8722;0.88 versus -1.56. Children in <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> (88% with a Centers for Disease Control and Prevention (CDC) category B or C) and <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK> (92% with World Health Organization (WHO) classification Stage 3 or 4) were more likely to be severely immuno-compromised compared to children in <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK> (8% with a CDC category B or C).</P>
<P>Participant inclusion and exclusion criteria are described in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Included studies randomly assigned children to isoniazid prophylaxis or placebo group. The dose of isoniazid prophylaxis (10 mg/kg with a variability of 8 mg/kg to 12 mg/kg) and frequency of treatment (either daily or three times weekly) were similar in <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> and <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK> compared to <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>, where children received 10 mg/kg to 20 mg/kg of isoniazid daily. Children assigned to the control groups received placebo with identical appearance to isoniazid prophylaxis tablets, and administered in a similar way to isoniazid prophylaxis in the respective studies.</P>
<P>In <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>, ART was initiated in 9% of children at baseline and in 22% during the trial. In <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>, ART was initiated at baseline in approximately 20% of HIV-positive children and in 98.9% within the first year. All children in <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK> were on ART. The analysis was stratified as such. In addition, only HIV-positive children in <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> and <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK> received 5 mg/kg of cotrimoxazole.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<P>Active TB was similarly defined across all three trials (see the '<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>' section).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-06-28 10:43:15 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded six studies on review of full articles, see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables for details.<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-07-04 13:45:34 +0100" MODIFIED_BY="[Empty name]">
<P>We have presented the risk of bias for each included trial in the 'Risk of bias' table in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables. The 'Risk of bias' summary presents the review authors&#8217; judgements on the risk of bias in each domain, for each trial separately (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), while the 'Risk of bias' graph presents the risk of bias in each domain as a percentage across all included trials (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). A summary of our findings on study methodological quality for each domain follows below.</P>
<ALLOCATION MODIFIED="2017-07-04 13:45:34 +0100" MODIFIED_BY="[Empty name]">
<P>Variable block random lists were used by <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> and <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK> for sequence generation; <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK> created the random list using permuted blocks. Treatment groups were centrally allocated in all three trials (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>; <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>). Methods of sequence generation were random and adequate for the three studies (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>; <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>). Treatment allocation was adequately concealed in all three trials (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>; <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-06-28 10:53:26 +0100" MODIFIED_BY="[Empty name]">
<P>In <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>, participants, personnel, and investigators assessing the outcome, including an independent outcome assessor, were blinded to study treatment allocation. Participants, caregivers, investigators, and end point review committee were unaware of study group assignment in <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>. Participants and personnel were blinded in <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>. The radiologist and the clinician (outcomes assessors) were blinded to the prophylactic regimen to which the child was allocated (<LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>). We assessed the three studies as having low risk of participant and personnel performance bias and detection bias (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>; <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-06-28 11:05:55 +0100" MODIFIED_BY="[Empty name]">
<P>The three studies were at low risk of attrition bias, because the attrition rate was below 20% in one study (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>), and all participants randomized were included in analysis in two trials (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-06-28 10:54:26 +0100" MODIFIED_BY="[Empty name]">
<P>We judged risk of reporting bias to be low in all three trials (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>; <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>). All outcomes stated in the study protocols were reported in the published manuscripts.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-06-28 10:54:57 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of other bias was unclear in one study; the data safety monitoring board recommended randomization into the placebo group to be stopped after 277 of the planned 432 participants were enrolled (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>). Two studies were at low risk of other potential sources of bias (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-07-17 12:32:53 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Isoniazid versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">HIV-positive children not on antiretroviral therapy (ART)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Active tuberculosis (TB)</HEADING>
<P>One trial from South Africa assessed the effects of isoniazid prophylaxis in HIV-positive children not taking ART. This trial was stopped early when 263 of 432 (61%) planned participants had been recruited, due to a result that had reached standard levels of statistical significance. Isoniazid prophylaxis reduce the number of children developing active TB by 69% (hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 participants, (review authors own figures), <I>low certainty evidence</I>). The number of events in this trial was very low. Therefore, we judged the result to be of low certainty, when downgraded for serious indirectness and imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Death</HEADING>
<P>In children not taking ART, isoniazid prophylaxis reduces death by more than 50% (risk ratio (RR) 0.46, 95% CI 0.22 to 0.95; 1 trial, 240 participants, (review authors own figures), <I>low certainty evidence</I>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). We downgraded the trial for serious indirectness and imprecision.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clinical adverse events (grade 3 or higher)</HEADING>
<P>One trial (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>) reported no clinical adverse events in children not on ART (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Laboratory adverse events (grade 3 or higher)</HEADING>
<P>One trial (182 participants) reported the number of children not on ART with laboratory adverse events (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Five and six children had haematological abnormalities (RR 0.83, 95% CI 0.26 to 2.63) in the isoniazid prophylaxis and placebo groups, respectively. None of the children in the isoniazid prophylaxis group, but two in the placebo group had liver enzyme abnormalities.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">HIV-positive children on antiretroviral therapy (ART)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Active TB</HEADING>
<P>In HIV-positive children on ART, isoniazid prophylaxis conferred neither benefit nor harm on active TB (RR 0.76, 95% CI 0.50 to 1.14; 3 trials, 737 participants, <I>very low certainty evidence</I>; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The trials and the meta-analysis were underpowered to detect clinically important effects and consequently the 95% CI is wide (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). The vast majority of data were from South Africa, limiting the broad generalization of the findings to other settings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Death</HEADING>
<P>Isoniazid prophylaxis conferred neither benefit nor harm on death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, <I>very low certainty evidence</I>; 
<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The trials were underpowered to detect clinically important effects of isoniazid prophylaxis on death (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). We downgraded the trials for indirectness and serious imprecision.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clinical adverse events (grade 3 or higher)</HEADING>
<P>Two trials (714 participants) reported number of clinical adverse events (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Three and two peripheral neuropathy abnormalities occurred in the isoniazid prophylaxis and placebo groups, respectively (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>); 15 and 24 other clinical adverse events respectively, occurred in the isoniazid prophylaxis and placebo groups (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>).</P>
<P>
<B>Laboratory adverse events (grade 3 or higher)</B>
</P>
<P>Three trials (795 participants) reported number of laboratory adverse events (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). There were 10 and 9 haematological abnormalities in the isoniazid prophylaxis and placebo groups (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>); and 15 and 13 liver enzyme abnormalities in the isoniazid prophylaxis and placebo groups, respectively (<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>; <LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-07-18 15:39:05 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-07-09 18:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>In HIV-positive children not taking antiretroviral therapy (ART), isoniazid prophylaxis may reduce active TB disease (low certainty evidence), and death (low certainty evidence). In HIV-positive children without known exposure to a TB source case, and on ART, isoniazid prophylaxis conferred neither benefit nor harm for active TB (very low certainty evidence) or death (very low certainty evidence). HIV treatment may modify the effect of TB preventive treatment. Clinical adverse events were similar between the isoniazid prophylaxis and placebo groups, both in children not on ART and those on ART. Laboratory adverse events were similar between the isoniazid prophylaxis and placebo groups, both in children not on ART and those on ART. In a secondary analysis of <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK> data, <LINK REF="STD-Le-Roux-2013" TYPE="STUDY">Le Roux 2013</LINK> showed that 16 (5.4%) out of 297 children developed severe liver injury while receiving isoniazid, but that only 1.7% of these cases were related to isoniazid prophylaxis.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-07-09 18:13:03 +0100" MODIFIED_BY="[Empty name]">
<P>Isoniazid preventive therapy is currently recommended for preventing TB infection in HIV-positive children. We included three trials (n = 991) in this review, which enrolled both young and older HIV-positive children, living in areas of high TB prevalence. Most of the data were from South Africa, limiting the generalizability of the review findings to other settings, given the variation in isoniazid resistance globally. The trials were underpowered to detect clinically important effects of isoniazid prophylaxis on active TB and death in HIV-positive children taking ART. ART is known to protect against TB disease, and adequately powered randomized controlled trials (RCTs) are therefore required to assess the possibility of isoniazid prophylaxis efficacy added to ART. Further data on isoniazid prophylaxis efficacy at varying levels of immunosuppression (HIV disease) are required.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-07-18 15:39:05 +0100" MODIFIED_BY="[Empty name]">
<P>We used the GRADE approach to rate the certainty of the evidence <LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>. In evaluating the certainty of RCT evidence, we considered the following in whether to downgrade the certainty of the evidence: methodological limitations, inconsistency in study results, indirectness, imprecision, and publication bias. We presented the evidence in two 'Summary of findings' tables for isoniazid prophylaxis efficacy; one for HIV-positive children not on ART (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), and the other for HIV-positive children on ART (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The evidence on the effect of isoniazid prophylaxis for active TB and death in HIV-positive children not on ART was of low certainty. The effect of isoniazid prophylaxis for active TB and death in HIV-positive children on ART was inconclusive and the evidence was of very low certainty. We downgraded the trials for serious indirectness and imprecision because all were conducted in one setting and were underpowered with wide confidence intervals.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-07-09 17:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted an extensive and comprehensive search of electronic databases, with no language restrictions, to identify published and unpublished trials. MZ and TY independently performed study selection. MZ and OA independently extracted the data and assessed the methodological quality of included studies. Review authors who authored an included study, were not involved in extraction of data and assessment of methodological quality of any included studies, to maintain independence of the review.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-07-09 18:14:13 +0100" MODIFIED_BY="[Empty name]">
<P>The results of this review were similar to those from a review of isoniazid prophylaxis in adults (<LINK REF="REF-Akolo-2010" TYPE="REFERENCE">Akolo 2010</LINK>). Isoniazid prophylaxis had a greater protective effect on TB disease in HIV-positive children not on ART, reducing the chance of developing active childhood TB disease by 69%, similar to the 62% reduction in risk of active disease, found in the adult review (<LINK REF="REF-Akolo-2010" TYPE="REFERENCE">Akolo 2010</LINK>). Evidence on impact of isoniazid prophylaxis on death in HIV-positive children not on ART, showed a 54% reduction in death (<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>). In contrast, isoniazid prophylaxis had no significant effect on TB disease and death in HIV-positive children on ART; these findings were consistent with the <LINK REF="REF-Akolo-2010" TYPE="REFERENCE">Akolo 2010</LINK> review in HIV-positive adults, reporting no effect on death, in a comparison of any drug for TB versus placebo. These findings may be consistent with the protective effect of ART, in reducing the risk of TB disease and death in HIV-positive children.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-07-09 18:14:22 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-07-09 18:14:22 +0100" MODIFIED_BY="[Empty name]">
<P>Isoniazid prophylaxis may reduce active tuberculosis (TB) disease and death in HIV-positive children not on antiretroviral therapy (ART). The WHO 2013 guidelines recommend ART for all HIV-positive children, which has to be started soon after diagnosis (<LINK REF="REF-WHO-2013" TYPE="REFERENCE">WHO 2013</LINK>). However, many children have delayed access to ART and coverage is not universal in most sub-Saharan settings, suggesting that any child awaiting ART in a high TB prevalence area, should have isoniazid prophylaxis until the child is virally suppressed and immune reconstituted. Baseline risk of HIV-positive children on ART, benefits and harms should be considered when making treatment decisions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-07-01 18:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of TB is substantially higher in HIV-positive children on ART compared to HIV-negative children from the same community. In <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>, children on ART had a higher rate of TB disease, 121 cases per 1000 child-years than HIV-negative children, 41 per 1000 child-years. Adequately powered trials assessing the impact of TB preventive therapy in HIV-positive children on ART are required. A target sample size of 848 HIV-positive children on ART will be required to have an 80% chance of detecting a 43% relative reduction, as significant at the 5% level, in the intervention group assuming a 14% baseline risk in active TB disease outcome. Trials that assess the long-term effects of TB prophylaxis are also needed to better assess the length of benefit in different settings. The three included trials investigated isoniazid prophylaxis versus placebo. There are no data on the efficacy of other TB preventive treatment regimens. Studies in adults included multiple-drug combination preventive treatment (<LINK REF="REF-Akolo-2010" TYPE="REFERENCE">Akolo 2010</LINK>). However adverse events leading to discontinuation of treatment were more common for multiple-drug therapy, as opposed to isoniazid treatment alone (<LINK REF="REF-Akolo-2010" TYPE="REFERENCE">Akolo 2010</LINK>).</P>
<P>Although most cases of definite TB in the included studies were sensitive to isoniazid prophylaxis, long-term data on the impact of isoniazid prophylaxis on <I>Mycobacterium tuberculosis </I>sensitivity are needed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-07-12 10:46:38 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Paul Garner, Co-ordinating Editor of the Cochrane Infectious Diseases Group (CIDG), for his guidance. We thank Olatunji Adetokunboh (OA) who assisted with data extraction and assessment of risk of bias.</P>
<P>Moleen Zunza and Taryn Young are partly supported by the Effective Health Care Research Consortium. This Consortium and the CIDG editorial base are funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this publication do not necessarily reflect UK government policy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-07-12 10:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>MZ: MZ is supported by the Effective Health Care Research Consortium funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this publication do not necessarily reflect UK government policy.</P>
<P>DG: Author of an included study</P>
<P>TY: TY is supported by the Effective Health Care Research Consortium funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this publication do not necessarily reflect UK government policy.</P>
<P>MC: Author of an included study</P>
<P>HZ: Author of an included study</P>
<P>To avoid potential bias, authors who were investigators on included studies did not do data extraction and methodological quality assessment of included studies.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-06-30 07:33:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>DG was the lead author for the first version of the review.</LI>
<LI>DG and HZ conducted the search and scrutinized identified studies for eligibility.</LI>
<LI>DG and TY assessed the methodological quality of included studies.</LI>
<LI>All authors critically reviewed the manuscript before submission (initial review).</LI>
<LI>MZ was the lead author of the review update.</LI>
<LI>MZ and TY screened the search results and assessed potential studies for eligibility.</LI>
<LI>MZ and a research assistant assessed the methodological quality of included studies.</LI>
<LI>DG, MC, and HZ critically reviewed the manuscript for content (review update). All authors approved the final version of the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-07-19 09:47:48 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of the 2009 version <LINK REF="REF-Gray-2009b" TYPE="REFERENCE">Gray 2009b</LINK> of this review. <LINK REF="REF-Gray-2009b" TYPE="REFERENCE">Gray 2009b</LINK> included one completed and two ongoing RCTs. The latter two RCTs are complete and now included in the update. An updated search identified no other studies. The methods now include the latest Cochrane risk of bias assessment tool, GRADE and Summary of findings tables. Findings are stratified into HIV positive children on ART and not on ART. Moleen Zunza joined the author team. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-23 10:47:48 +0100" MODIFIED_BY="Anne-Marie Stephani">
<STUDIES MODIFIED="2017-07-09 18:18:54 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-07-30 20:25:54 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Gray-2014" MODIFIED="2015-08-06 15:58:43 +0100" MODIFIED_BY="[Empty name]" NAME="Gray 2014" YEAR="2013">
<REFERENCE MODIFIED="2015-08-06 15:58:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gray DM, Workman LJ, Lombard CJ, Jennings T, Innes S, Grobbelaar CJ, et al</AU>
<TI>Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>2014</YR>
<VL>18</VL>
<NO>3</NO>
<PG>322-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229236"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229235"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madhi-2011" MODIFIED="2015-01-16 07:46:27 +0000" MODIFIED_BY="Joy Oliver" NAME="Madhi 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-01-16 07:46:27 +0000" MODIFIED_BY="Joy Oliver" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al</AU>
<TI>Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>365</VL>
<NO>1</NO>
<PG>21-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229238"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229237"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zar-2007" MODIFIED="2015-08-06 15:44:44 +0100" MODIFIED_BY="[Empty name]" NAME="Zar 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-08-06 15:44:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al</AU>
<TI>Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>334</VL>
<PG>136-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229240"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229239"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-07-09 18:18:54 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Frigati-2011" MODIFIED="2017-07-09 18:18:54 +0100" MODIFIED_BY="[Empty name]" NAME="Frigati 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-07-09 18:18:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ</AU>
<TI>The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting</TI>
<SO>Thorax</SO>
<YR>2011</YR>
<VL>66</VL>
<NO>6</NO>
<PG>496-501</PG>
<IDENTIFIERS MODIFIED="2015-02-12 06:11:51 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6616441"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229241"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hesseling-2012" MODIFIED="2015-01-16 07:48:37 +0000" MODIFIED_BY="Joy Oliver" NAME="Hesseling 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-01-16 07:48:37 +0000" MODIFIED_BY="Joy Oliver" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hesseling AC, Kim S, Madhi S, Nachman S, Schaaf HS, Violari A, et al</AU>
<TI>High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>2</NO>
<PG>192-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3229244"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229243"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iro-2013" MODIFIED="2017-06-30 11:15:18 +0100" MODIFIED_BY="[Empty name]" NAME="Iro 2013" YEAR="">
<REFERENCE MODIFIED="2017-06-30 11:15:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iro MA, Brown N</AU>
<TI>Isoniazid prophylaxis started at 3-4 months of life does not prevent tuberculosis disease or infection in both HIV-infected and uninfected children</TI>
<SO>Archives of Disease in Childhood: Education and Practice Edition</SO>
<YR>2013</YR>
<VL>98</VL>
<NO>1</NO>
<PG>40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6616442"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229245"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-le-Roux-2009" MODIFIED="2017-06-30 11:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="le Roux 2009" YEAR="2009">
<REFERENCE MODIFIED="2017-06-30 11:16:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>le Roux SM, Cotton MF, Golub JE, le Roux DM, Workman L, Zar HJ</AU>
<TI>Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules</TI>
<SO>BMC Medicine</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>67</NO>
<PG>1-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6616443"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229247"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Roux-2013" MODIFIED="2017-06-30 11:16:40 +0100" MODIFIED_BY="[Empty name]" NAME="Le Roux 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-06-30 11:16:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>le Roux SM, Cotton MF, Myer L, le Roux DM, Schaaf HS, Lombard CJ, et al</AU>
<TI>Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>2013</YR>
<VL>17</VL>
<NO>1</NO>
<PG>26-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6616444"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229249"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marais-2013" MODIFIED="2017-06-30 11:18:05 +0100" MODIFIED_BY="[Empty name]" NAME="Marais 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-06-30 11:18:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marais BJ, Graham SM, Maeurer M, Zumla A</AU>
<TI>Progress and challenges in childhood tuberculosis</TI>
<SO>Lancet. Infectious Diseases</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>4</NO>
<PG>287-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6616445"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3229251"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-11-18 04:14:32 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-07-18 15:42:15 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-07-13 12:09:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Akolo-2010" MODIFIED="2015-02-17 06:35:52 +0000" MODIFIED_BY="[Empty name]" NAME="Akolo 2010" TYPE="COCHRANE_REVIEW">
<AU>Akolo C, Adetifa I, Shepperd S, Volmink J</AU>
<TI>Treatment of latent infection in HIV infected persons</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-02-17 06:35:52 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-02-17 06:35:52 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000171.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berggren-Palme-2002" MODIFIED="2015-01-16 07:26:31 +0000" MODIFIED_BY="Joy Oliver" NAME="Berggren Palme 2002" TYPE="JOURNAL_ARTICLE">
<AU>Berggren Palme I, Gudetta B, Bruchfield J, Muhe L, Giesecke J</AU>
<TI>Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1053-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burman-2005" MODIFIED="2017-07-12 10:50:06 +0100" MODIFIED_BY="[Empty name]" NAME="Burman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Burman WJ</AU>
<TI>Issues in the management of HIV-related tuberculosis</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>283-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chintu-2005" MODIFIED="2017-06-30 11:42:13 +0100" MODIFIED_BY="[Empty name]" NAME="Chintu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chintu C, Mwaba P</AU>
<TI>Tuberculosis in children with human immunodeficiency virus infection</TI>
<SO>The International Journal of Tuberculosis Lung Disease</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>5</NO>
<PG>477-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2006" MODIFIED="2017-06-30 11:42:40 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cohen T, Lipsitch M, Walensky RP, Murray M</AU>
<TI>Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis co-infected populations</TI>
<SO>Proceeding of the National Academy of Sciences of the United States of America</SO>
<YR>2006</YR>
<VL>103</VL>
<NO>18</NO>
<PG>7042-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2017-06-30 11:43:10 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2008" TYPE="BOOK_SECTION">
<AU>Deeks J, Higgins JP, Altman D</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analysis</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>243-96</PG>
<ED>Higgins JP, Green S</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donald-2000" NAME="Donald 2000" TYPE="JOURNAL_ARTICLE">
<AU>Donald PR</AU>
<TI>Childhood tuberculosis</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>187-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donald-2002" NAME="Donald 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donald PR</AU>
<TI>Childhood tuberculosis: out of control?</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>2002</YR>
<VL>8</VL>
<PG>178-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edmonds-2009" MODIFIED="2017-06-30 11:43:22 +0100" MODIFIED_BY="[Empty name]" NAME="Edmonds 2009" TYPE="JOURNAL_ARTICLE">
<AU>Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F</AU>
<TI>Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<PG>1612-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foster-2003" MODIFIED="2017-06-30 11:43:33 +0100" MODIFIED_BY="[Empty name]" NAME="Foster 2003" TYPE="JOURNAL_ARTICLE">
<AU>Foster K, Alton H</AU>
<TI>Chronic lung infection in children</TI>
<SO>Paediatric Respiratory Reviews</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>225-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Getahun-2010" MODIFIED="2017-07-12 10:50:20 +0100" MODIFIED_BY="[Empty name]" NAME="Getahun 2010" TYPE="JOURNAL_ARTICLE">
<AU>Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al</AU>
<TI>Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions</TI>
<SO>AIDS</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>5</NO>
<PG>S57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goletti-1996" MODIFIED="2017-06-30 11:44:02 +0100" MODIFIED_BY="[Empty name]" NAME="Goletti 1996" TYPE="JOURNAL_ARTICLE">
<AU>Goletti D, Weisman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al</AU>
<TI>Effect of mycobacterium tuberculosis on HIV replication: role of immune activation</TI>
<SO>Journal of Immunology</SO>
<YR>1996</YR>
<VL>157</VL>
<PG>1271-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2014" MODIFIED="2017-06-30 11:44:23 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro GDT 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grant-2005" MODIFIED="2015-12-12 06:20:32 +0000" MODIFIED_BY="[Empty name]" NAME="Grant 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grant AD, Charalambous S, Fielding KL, Day JH, Corbertt EL, Chaisson RE, et al</AU>
<TI>Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>22</NO>
<PG>2719-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray-2009a" MODIFIED="2017-06-30 11:44:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gray 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Gray D, Nuttall J, Lombard C, Davies MA, Workman L, Apolles P, et al</AU>
<TI>Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis</TI>
<SO>Journal of Tropical Pediatrics</SO>
<YR>2010</YR>
<VL>56</VL>
<NO>3</NO>
<PG>159-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2017-06-30 11:44:56 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hesseling-2005" MODIFIED="2017-06-30 11:45:09 +0100" MODIFIED_BY="[Empty name]" NAME="Hesseling 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hesseling AC, Westra AE, Werschkull H, Donald PR, Beyers N, Hussey GD, et al</AU>
<TI>Outcome of HIV infected children with culture confirmed tuberculosis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2005</YR>
<VL>90</VL>
<PG>1171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hesseling-2009" MODIFIED="2017-06-30 11:45:23 +0100" MODIFIED_BY="[Empty name]" NAME="Hesseling 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B, et al</AU>
<TI>High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2009</YR>
<VL>48</VL>
<PG>108&#8211;14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-06-30 11:45:38 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ikeogu-1997" MODIFIED="2014-11-18 04:18:44 +0000" MODIFIED_BY="[Empty name]" NAME="Ikeogu 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ikeogu Mo, Wolf B, Mathe S</AU>
<TI>Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>124&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeena-1998" NAME="Jeena 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jeena PM, Coovadia HM, Thula SA, Blythe D, Buckels NJ, Chetty R</AU>
<TI>Persistent and chronic lung disease in HIV-1-infected and uninfected African children</TI>
<SO>AIDS</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>1185-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeena-2002" NAME="Jeena 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jeena PM, Pillay P, Pillay T, Coovadia HM</AU>
<TI>Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa</TI>
<SO>The International Journal of Tuberculosis and Lung Disease</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>672-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kochi-1991" NAME="Kochi 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kochi A</AU>
<TI>The global tuberculosis situation and the new strategy of the World Health Organisation</TI>
<SO>Tubercle</SO>
<YR>1991</YR>
<VL>72</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2017-07-11 14:27:16 +0100" MODIFIED_BY="[Empty name]" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gtzsche PC, Ioannidis JP, et al</AU>
<TI>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b2700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinson-2009" MODIFIED="2017-06-30 11:45:53 +0100" MODIFIED_BY="[Empty name]" NAME="Martinson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Martinson NA, Moultrie H, van Niekerk R, Barry G, Coovadia A, Cotton M, et al</AU>
<TI>HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>7</NO>
<PG>862&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mukadi-1997" MODIFIED="2017-07-02 12:19:49 +0100" MODIFIED_BY="[Empty name]" NAME="Mukadi 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mukadi YD, Wiktor Z, Coulibaly IM, Coulibaly D, Mbengue A, Folquet AM, et al</AU>
<TI>Impact of HIV infection on the development, clinical presentation and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire</TI>
<SO>AIDS</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1151-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Narita-1998" NAME="Narita 1998" TYPE="JOURNAL_ARTICLE">
<AU>Narita M, Ashkin D, Hollender ES, Pitchenik AE</AU>
<TI>Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>1</NO>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2004" NAME="Nelson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nelson LJ, Wells CD</AU>
<TI>Global epidemiology of childhood tuberculosis</TI>
<SO>The International Journal of Tuberculosis and Lung Disease</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>5</NO>
<PG>636-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIAID-2014" MODIFIED="2017-07-03 09:42:44 +0100" MODIFIED_BY="[Empty name]" NAME="NIAID 2014" TYPE="OTHER">
<AU>U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS</AU>
<TI>Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 2014</TI>
<SO>https://rsc.tech-res.com/docs/default-source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8</SO>
<YR>(accessed 03 July 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perriens-1995" MODIFIED="2017-07-13 12:09:43 +0100" MODIFIED_BY="[Empty name]" NAME="Perriens 1995" TYPE="JOURNAL_ARTICLE">
<AU>Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, et al</AU>
<TI>Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>12</NO>
<PG>779-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puthanakit-2006" MODIFIED="2017-06-30 11:46:20 +0100" MODIFIED_BY="[Empty name]" NAME="Puthanakit 2006" TYPE="JOURNAL_ARTICLE">
<AU>Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirianthana V</AU>
<TI>Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>1</NO>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rangaka-2014" MODIFIED="2017-06-30 11:46:29 +0100" MODIFIED_BY="[Empty name]" NAME="Rangaka 2014" TYPE="JOURNAL_ARTICLE">
<AU>Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al</AU>
<TI>Isoniazid plus antiretroviral therapy to prevent tuberculosis:a randomised double-blind, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2014</YR>
<VL>384</VL>
<NO>9944</NO>
<PG>682-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ren-2008" MODIFIED="2017-06-30 11:46:43 +0100" MODIFIED_BY="[Empty name]" NAME="Ren 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al</AU>
<TI>Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2008</YR>
<VL>47</VL>
<PG>566&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ren-2009" MODIFIED="2017-06-30 11:46:53 +0100" MODIFIED_BY="[Empty name]" NAME="Ren 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al</AU>
<TI>Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2009</YR>
<VL>50</VL>
<PG>439&#8211;43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-2014" MODIFIED="2017-06-30 11:47:05 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schaaf-1998" NAME="Schaaf 1998" TYPE="JOURNAL_ARTICLE">
<AU>Schaaf HS, Geidenduys A, Gie RP, Cotton MF</AU>
<TI>Culture-positive tuberculosis in human immunodeficiency virus type-1-infected children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>7</VL>
<PG>599-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schaaf-2005" MODIFIED="2017-06-30 11:47:19 +0100" MODIFIED_BY="[Empty name]" NAME="Schaaf 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC</AU>
<TI>Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>8</NO>
<PG>685-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smieja-1999" MODIFIED="2015-02-17 06:35:41 +0000" MODIFIED_BY="[Empty name]" NAME="Smieja 1999" TYPE="COCHRANE_REVIEW">
<AU>Smieja MJ, Marchettu CA, Cook DJ, Smaill FM</AU>
<TI>Isoniazid for preventing tuberculosis in non-HIV infected persons</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-02-17 06:35:41 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-02-17 06:35:41 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001363"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2009" MODIFIED="2017-06-30 11:47:31 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2009" TYPE="JOURNAL_ARTICLE">
<AU>Smith K, Kuhn L, Coovadia A, Meyers T, Hub CC, Reitz C, et al</AU>
<TI>Immune reconstitution inflammatory syndrome among HIV infected South African infants initiating antiretroviral therapy</TI>
<SO>AIDS</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1097&#8211;107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNAIDS_x002f_WHO-2013" MODIFIED="2017-06-30 11:47:44 +0100" MODIFIED_BY="[Empty name]" NAME="UNAIDS/WHO 2013" TYPE="OTHER">
<AU>UNAIDS/WHO</AU>
<TI>AIDS epidemic update. September</TI>
<SO>www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/201309_epi_core_en.pdf</SO>
<YR>(accessed 25 November 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verver-2005" MODIFIED="2017-06-30 11:47:56 +0100" MODIFIED_BY="[Empty name]" NAME="Verver 2005" TYPE="JOURNAL_ARTICLE">
<AU>Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, et al</AU>
<TI>Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<PG>1430&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2008" MODIFIED="2017-06-30 11:48:06 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 2008" TYPE="JOURNAL_ARTICLE">
<AU>Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ</AU>
<TI>Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy</TI>
<SO>BMC Pediatrics</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whalen-1995" MODIFIED="2015-01-16 07:31:26 +0000" MODIFIED_BY="Joy Oliver" NAME="Whalen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J</AU>
<TI>Accelerated course of human immunodeficiency virus infection after tuberculosis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<PG>129-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010" MODIFIED="2017-06-30 11:48:20 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2010" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision</TI>
<SO>www.who.int/hiv/pub/paediatric/infants2010/en/index.html</SO>
<YR>(accessed 16 November 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2017-06-30 11:48:31 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2011" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings</TI>
<SO>www.whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf</SO>
<YR>(accessed 16 November 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2012" MODIFIED="2017-06-30 11:49:51 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2012" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global Tuberculosis Report, 2012</TI>
<SO>apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf</SO>
<YR>(accessed June 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2013" MODIFIED="2017-06-30 11:50:06 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2013" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013</TI>
<SO>www.who.int/hiv/pub/guidelines/arv2013/download/en/</SO>
<YR>(accessed prior to 6 June 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zampoli-2007" MODIFIED="2017-06-30 11:49:28 +0100" MODIFIED_BY="[Empty name]" NAME="Zampoli 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zampoli M, Kilborn T, Eley B</AU>
<TI>Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>4</NO>
<PG>417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zar-2001" MODIFIED="2017-07-02 12:18:58 +0100" MODIFIED_BY="[Empty name]" NAME="Zar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Zar HJ, Manslo D, Tannebaum E, Klein M, Argent A, Eley B, et al</AU>
<TI>Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa</TI>
<SO>Acta Paediatrica</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>2</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-07-18 15:42:15 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gray-2007" MODIFIED="2017-06-30 11:50:24 +0100" MODIFIED_BY="[Empty name]" NAME="Gray 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Gray DM, Zar HJ, Cotton M</AU>
<TI>The impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-06-06 04:16:47 +0100" MODIFIED_BY="Clare Dooley"><IDENTIFIER MODIFIED="2017-06-06 04:16:46 +0100" MODIFIED_BY="Clare Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD006418"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gray-2009b" MODIFIED="2017-07-18 15:42:15 +0100" MODIFIED_BY="[Empty name]" NAME="Gray 2009b" TYPE="COCHRANE_REVIEW">
<AU>Gray DM, Young T, Zar H, Cotton M</AU>
<TI>Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-06-06 04:20:47 +0100" MODIFIED_BY="Clare Dooley"><IDENTIFIER MODIFIED="2017-06-06 04:20:46 +0100" MODIFIED_BY="Clare Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD006418.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-08-08 14:32:58 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-08-08 14:32:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-07-12 10:47:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gray-2014">
<CHAR_METHODS MODIFIED="2017-06-30 07:45:53 +0100" MODIFIED_BY="[Empty name]">
<P>Trial design: double-blind, randomized placebo-controlled trial.</P>
<P>Follow-up: full blood count, liver function tests, urea and electrolyte tests, percentage of CD4 cells and viral load were measured at baseline and 6-monthly. CXR was performed at baseline, and additional CXRs were taken if clinically indicated.</P>
<P>Adverse events: symptoms of adverse reactions to INH were recorded at each study visit.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-30 09:36:56 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants: 167</P>
<P>Median (IQR) age at baseline: 35 months (15 to 65)</P>
<P>Inclusion criteria: age &gt; 8 weeks, on ART for greater than 2 months, weight &gt; 2.5 kg, adherence to ART of &gt; 90%, prior history of TB treatment or prophylaxis, informed consent, resident in the area, access to transport.</P>
<P>Exclusion criteria: chronic diarrhoea, currently using isoniazid prophylaxis, exposure to a TB contact, history of prior isoniazid hypersensitivity, severe anaemia (haemoglobin less than 7 gm/dL), neutropenia (absolute neutrophil count less than 400 cells/L), thrombocytopenia (platelet count less than 50 000/L), non-reversible renal failure.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-30 09:32:44 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Isoniazid, 10 mg/kg/dose with a variability of 8 mg/kg to 12 mg/kg, either three times weekly or daily for a median duration of 34 months. 
</LI>
<LI>Placebo, had an identical appearance to isoniazid tablet, received either three times weekly or daily for a median duration of 34 months.</LI>
</OL>
<P>All children were on ART and had adherence of at least 90% at baseline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-30 07:45:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Active TB</LI>
<LI>Death</LI>
<LI>Adverse events</LI>
</OL>
<P>Not included in this review</P>
<OL>
<LI>Adherence to TB treatment</LI>
<LI>Hospital admissions</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-12 10:47:21 +0100" MODIFIED_BY="[Empty name]">
<P>Definitions:</P>
<P>- Definite TB: a microbiological or histological identification of <I>Mycobacterium tuberculosis</I>.</P>
<P>- Probable TB: based on a combination of typical clinical symptoms and signs, tuberculin skin testing, chest radiography, a history of close TB contact, and a documented response to antimycobacterial therapy.</P>
<P>Country: South Africa</P>
<P>Prevalence of isoniazid resistance: 0%</P>
<P>Positive tuberculin test: 16%</P>
<P>Funding: The study was funded by the Medical Research Council, South Africa; the National Research Foundation, Department of Health, South Africa; and the Discovery Foundation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-12 10:47:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madhi-2011">
<CHAR_METHODS MODIFIED="2017-06-30 07:39:36 +0100" MODIFIED_BY="[Empty name]">
<P>Trial design: multicentre, phase 2&#8211;3, randomized, double-blind, placebo-controlled trial.</P>
<P>Follow-up: TB disease-free survival and incidence of TB disease at 96 weeks after randomization.</P>
<P>Adverse events: liver enzyme tests, blood counts, clinical neurologic evaluations for peripheral neuropathy, at scheduled visits every 3 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-30 09:38:06 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants: 547</P>
<P>Median (IQR) age at baseline: 3 months (3 to 4)</P>
<P>Inclusion criteria: age of 91 to 120 days, received Bacille Calmette-Guerin (BCG) vaccine, no history of TB in the infant, known exposure to a microbiological confirmed case of TB, or active anti-TB treatment in the mother at the time of the infant's birth, no evidence of failure to thrive, recurrent pneumonia, chronic diarrhoea, or immunosuppressive conditions other than HIV infection.</P>
<P>Exclusion criteria: previous diagnosis of TB infection, previous receipt of isoniazid, contact with a known acid fast bacilli (AFB) sputum smear or culture-positive case of TB before study entry, current acute or recurrent (3 or more prior episodes) lower respiratory tract disease, chronic persistent diarrhoea, significant drop in weight or failure to gain weight appropriately during a 2- to 3-month period, contraindications for use of isoniazid or SMX/TMP, require certain medications, known or suspected immune system diseases other than HIV, current or previous diagnosis of or treatment for cancer, current immunosuppressive therapy greater than 1 mg/kg/day of prednisone or equivalent, anticipated long-term oral or intravenous corticosteroid therapy (greater than 3 weeks), those receiving nonsteroidal anti-inflammatory agents and inhaled corticosteroids were not excluded, grade 3 or greater AST/SGOT, ALT/SGPT, ANC, haemoglobin, platelet count, rash, neuropathy, or myopathy at screening, any grade 4 clinical or laboratory toxicity within 14 days prior to study entry, other acute or chronic conditions that, in the opinion of the investigator, may interfere with the study.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-30 10:20:57 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Isoniazid prophylaxis, daily, at a dose of 10 mg/kg to 20 mg/kg of body weight for 96 weeks</LI>
<LI>Placebo, daily for 96 weeks</LI>
</OL>
<P>At baseline, 98.7% of the children were on ART. ART mainly included stavudine, lamivudine, and lopinavir-ritonavir or zidovudine, lamivudine, and lopinavir&#8211; ritonavir, following per country-specific guidelines.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-30 07:39:59 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Active TB</LI>
<LI>Death</LI>
<LI>Adverse events</LI>
</OL>
<P>Not included in this review</P>
<OL>
<LI>Compliance with study drug</LI>
<LI>HIV disease progression</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-12 10:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Definitions:</P>
<P>- Definite TB: a microbiological or histological identification of <I>Mycobacterium tuberculosis</I>.</P>
<P>- Probable TB: based on a combination of typical clinical symptoms and signs, tuberculin skin testing, chest radiography, a history of close TB contact, and a documented response to antimycobacterial therapy.</P>
<P>All infants were enrolled in the first 6 months of life. The study included HIV-uninfected children with outcomes defined differently for this subgroup, however, analysis of HIV-uninfected children was not included in this review. All HIV-infected children also received trimethoprim&#8211;sulfamethoxazole prophylaxis 5 mg/kg according to WHO guidelines.</P>
<P>TB disease-free survival was defined as the first occurrence of death from any cause or TB disease, 96 weeks after randomization. HIV disease progression, was defined as the first occurrence of worsening of the Centers for Diseases Control and Prevention (CDC) clinical categorization of HIV infection or death.</P>
<P>Country: South Africa, Botswana</P>
<P>Prevalence of isoniazid resistance (95% CI): 26% (9 to 51)</P>
<P>Positive tuberculin test: not reported</P>
<P>Funding: The study was supported by the Statistical and Data Analysis Center at the Harvard School of Public Health, under NIAID cooperative agreements with the Pediatric AIDS Clinical Trials Group (5 U01 AI41110) and the IMPAACT Group (1 U01 AI068616); NIAID and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network (NICHD contract number N01-DK-9-001/HHSN267200-800001C); Secure the Future Fund, a philanthropy program sponsored by Bristol-Myers Squibb.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-08 14:32:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zar-2007">
<CHAR_METHODS MODIFIED="2017-06-30 07:41:29 +0100" MODIFIED_BY="[Empty name]">
<P>Trial design: double-blind, placebo-controlled trial.</P>
<P>Follow-up: children underwent a tuberculin skin test and chest radiography if clinically indicated.</P>
<P>Adverse events: alanine transaminase were measured one and three months after randomization and thereafter six-monthly or more frequently if clinically indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-08 14:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants: 277</P>
<P>Median (IQR) age at baseline: 25 months (9 to 52)</P>
<P>Inclusion criteria: age &gt; 8 weeks, weight &gt; 2.5 kg, access to transport, informed consent, children stable on ART for two to three months.</P>
<P>Exclusion criteria: chronic diarrhoea, current use of or need for isoniazid prophylaxis, previous hypersensitivity to isoniazid or sulphur containing drugs, haemoglobin &lt; 70 g/L, neutrophil count &lt; 400 cell/uL, platelet count &lt; 50,000 x10<SUP>9</SUP>/L, non-reversible renal failure.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-30 10:30:25 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Isoniazid: 10 mg/kg/dose with a variability of 8 mg/kg to 12 mg/kg, either daily or three times a week on Monday, Wednesday, and Friday for a median duration of 5.7 months.</LI>
<LI>Placebo, identical in appearance to isoniazid tablets, either daily or three times a week on Monday, Wednesday, and Friday for a median duration of 5.7 months.</LI>
</OL>
<P>ART was not widely available. Some children obtained treatment through participation in pharmaceutical trials or charitable donations. 23 of 263 (9%) were on ART at enrolment and 58 (22%) started treatment during the trial.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-30 07:41:29 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Active TB</LI>
<LI>Death</LI>
<LI>Adverse events</LI>
</OL>
<P>Not included in this review: none<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-11 19:10:44 +0100" MODIFIED_BY="[Empty name]">
<P>Definitions:</P>
<P>- Definite TB: a microbiological or histological identification of <I>Mycobacterium tuberculosis</I>.</P>
<P>- Probable TB: based on a combination of typical clinical symptoms and signs, tuberculin skin testing, chest radiography, a history of close TB contact, and a documented response to antimycobacterial therapy.</P>
<P>Cotrimoxazole (5 mg/kg/dose of the trimethoprim component): Given to all children &lt; 12 months and those older with clinical CDC category B or C disease, in those with severe immunological impairment (CD4 count of &lt; 15% of total lymphocyte count), or in those with previous episode of <I>Pneumocystis jirovecii</I> pneumonia. Study was planned to run for 2 years, however, the placebo arm was terminated early on the recommendation of the data safety monitoring board on the basis of the results of interim analyses. About 30% of the children received ART during the trial with similar percentages in isoniazid and placebo groups. Adverse events were graded 1 to 4 according to the toxicity criteria of the National Institutes of Health's division of AIDS (DAIDS). Grade 3 and 4 events were reported.</P>
<P>Country: South Africa</P>
<P>Prevalence of isoniazid resistance: 0%</P>
<P>Positive tuberculin test: 9%</P>
<P>Funding: The study was supported by Rockefeller Foundation, USA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations: </P>
<P>ALT/SGPT: Alanine aminotransferase (serum glutamic pyruvic transaminase)<BR/>ANC: Absolute neutrophil count<BR/>ART: Antiretroviral therapy<BR/>AST/SGOT: Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase)<BR/>CDC: Centers for Diseases Control and Prevention<BR/>CXR: Chest x-rays<BR/>INH: Isoniazid<BR/>SMX/TMP: Trimethoprim/Sulfamethoxazole<BR/>TB: Tuberculosis<BR/>WHO: World Health Organization<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-07-12 10:49:09 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-07-12 10:49:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frigati-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 10:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>A cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-30 07:44:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hesseling-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-30 07:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>Secondary analysis of <LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-30 07:44:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iro-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-30 07:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>Commentary.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-30 07:45:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-le-Roux-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-30 07:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>Not addressing review outcomes; secondary analysis of <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-30 07:45:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Roux-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-30 07:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>Cohort study. Secondary analysis of <LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-30 07:45:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marais-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-30 07:45:06 +0100" MODIFIED_BY="[Empty name]">
<P>Commentary.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-11-18 04:14:32 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2014">
<DESCRIPTION>
<P>Randomization list was created using permuted blocks, stratified by HIV infection status and balanced by study site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2011">
<DESCRIPTION>
<P>"Randomization list was created usingpermuted blocks".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:44:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zar-2007">
<DESCRIPTION>
<P>A variable block random list was used. Generation of allocation sequence was achieved by variable blocked randomization lists prepared by the trial statistician and sent to each trial site pharmacist in a sealed opaque envelope.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2014">
<DESCRIPTION>
<P>Treatment groups were centrally allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-05 12:19:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2011">
<DESCRIPTION>
<P>Treatment groups were centrally allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:44:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zar-2007">
<DESCRIPTION>
<P>Central allocation (pharmacists labelled trial drugs with sequential numbers). The participants were allocated study numbers sequentially by the study nurse at enrolment. They were then sequentially allocated to treatment group by the pharmacist according to the prepared list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2014">
<DESCRIPTION>
<P>"Placebo had an identical appearance to INH tablets and was administered in a double blind matter".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-18 04:15:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2011">
<DESCRIPTION>
<P>Participants, caregivers and investigators were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-30 07:44:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zar-2007">
<DESCRIPTION>
<P>Placebo was manufactured to havean identical appearance to isoniazid, participants and personnel were blinded to study assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2014">
<DESCRIPTION>
<P>"The chest radiographs were reported by a radiologist blinded to the prophylactic regimen to which the child was allocated. Diagnosis of TB was independently reviewed by an experienced clinician blinded to study randomisation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-30 07:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2011">
<DESCRIPTION>
<P>"End point review committee was unaware of study-group assignments".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-30 07:44:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zar-2007">
<DESCRIPTION>
<P>Investigators assessing the outcome and were blinded, the diagnosis of probable TB was subject to independent review by a blinded investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2014">
<DESCRIPTION>
<P>Intention-to-treat analysis was followed. All participants randomized were included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-30 07:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2011">
<DESCRIPTION>
<P>Intention-to-treat analysis was followed, however, its not clear if all enrolled participants were included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-30 07:44:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zar-2007">
<DESCRIPTION>
<P>Attrition rate was very low, &lt; 20%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2014">
<DESCRIPTION>
<P>Outcomes stated in the protocol were included in the published manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2011">
<DESCRIPTION>
<P>All important outcomes stated in the study protocol were reported in the published manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:44:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zar-2007">
<DESCRIPTION>
<P>All outcomes stated in the study protocol were the same as those in the published manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gray-2014">
<DESCRIPTION>
<P>None suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:41:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2011">
<DESCRIPTION>
<P>None suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-30 07:44:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zar-2007">
<DESCRIPTION>
<P>The data safety monitoring board recommended randomization into placebo to be stopped after 277 of the planned 432 were enrolled. The placebo arm was ended on 17 May 2004 on the recommendation of the data safety monitoring board on the basis of the results of interim analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-07-11 19:52:14 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-07-11 19:51:10 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-07-11 19:51:10 +0100" MODIFIED_BY="[Empty name]">Isoniazid prophylaxis compared to placebo for HIV-positive children not on antiretroviral therapy (ART)</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Isoniazid prophylaxis compared to placebo for HIV-positive children not on antiretroviral therapy (ART)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> HIV-positive children not taking ART<BR/>
<B>Settings:</B> any setting<BR/>
<B>Intervention:</B> isoniazid prophylaxis daily or three times weekly<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comment</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Isoniazid prophylaxis </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Active TB</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>10 per 100</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>3 per 100</P>
<P>(1 to 9)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.31</P>
<P>(95% CI 0.11 to 0.87)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>240</P>
<P>(1 trial)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3,4,5</SUP>
</P>
<P>due to serious indirectness and imprecision</P>
</TD>
<TD>
<P>Isoniazid prophylaxis may reduce active TB</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Death</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>17 per 100</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>8 per 100</P>
<P>(8 per 17)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.46</P>
<P>(95% CI 0.22 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>240</P>
<P>(1 trial)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3,4,5</SUP>
</P>
<P>due to serious indirectness and imprecision</P>
</TD>
<TD>
<P>Isoniazid prophylaxis may reduce death</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Abbreviations: CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>HR</B>: hazard ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High certainty:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate certainty:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low certainty:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low certainty:</B> we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No serious risk of bias: this trial was at low risk of selection bias, and adequately blinded study participants and personnel. However, the study was stopped early on the recommendation of the data safety monitoring board after only 277 of the planned 432 were enrolled. Not downgraded.<BR/>
<SUP>2</SUP>No serious inconsistency: a single trial.<BR/>
<SUP>3</SUP>Downgraded by 1 for serious indirectness: this single trial is from a single setting in South Africa. Broad generalization of this result to other settings is difficult given the variation in isoniazid resistance worldwide.<BR/>
<SUP>4</SUP>Downgraded by 1 for serious imprecision: there were very few events in this trial and as such the finding is fragile. The original paper reports the result using a hazard ratio and the result reached standard levels of statistical significance.<BR/>
<SUP>5</SUP>We reported the study authors' data.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-07-11 19:52:14 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-07-11 19:51:41 +0100" MODIFIED_BY="[Empty name]">Isoniazid prophylaxis compared to placebo for HIV-positive children on antiretroviral therapy (ART)</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Isoniazid prophylaxis compared to placebo for HIV-positive children on antiretroviral therapy (ART)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> HIV-positive children on ART<BR/>
<B>Settings:</B> any setting<BR/>
<B>Intervention:</B> isoniazid prophylaxis daily or three times weekly<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Isoniazid prophylaxis </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Active TB </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 100</B>
<BR/>(7 to 15)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.76 </B>
<BR/>(0.50 to 1.14)</P>
</TD>
<TD VALIGN="TOP">
<P>737<BR/>(3 trials)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
<P>due to serious indirectness and imprecision</P>
</TD>
<TD>
<P>We don't know if Isoniazid prophylaxis reduce active TB</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 100</B>
<BR/>(3 to 11)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.45</B>
</P>
<P>(0.78 to 2.72)</P>
</TD>
<TD VALIGN="TOP">
<P>737<BR/>(3 trials)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,5</SUP>
</P>
<P>due to serious indirectness and imprecision</P>
</TD>
<TD>
<P>We don't know if Isoniazid prophylaxis reduce death</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Abbreviations: CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High certainty:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate certainty:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low certainty:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low certainty:</B> we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No serious risk of bias: trials were at low risk of selection bias. Both studies adequately blinded study participants and personnel.<BR/>
<SUP>2</SUP>No serious inconsistency: statistical heterogeneity was low.<BR/>
<SUP>3</SUP>Downgraded by 1 for serious indirectness: all trials were conducted in South Africa. Given the variation in isoniazid resistance globally it is difficult to generalize this result to all settings.<BR/>
<SUP>4</SUP>Downgraded by 2 for serious imprecision: to confidently detect a 25% relative reduction in active TB would require a sample size of nearly 3000 participants. This meta-analysis is therefore underpowered, and the 95% CI includes both appreciable benefit and no effect.<BR/>
<SUP>5</SUP>Downgraded by 2 for serious imprecision: there were few events and the 95% CI includes both appreciable harm and no effect.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-07-11 19:52:53 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-07-11 19:52:53 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-07-11 19:52:53 +0100" MODIFIED_BY="[Empty name]">Number of children with adverse events and number of adverse events (of grade 3 or higher) in HIV-positive children on antiretroviral therapy (ART) and not on ART, by study</TITLE>
<TABLE COLS="9" ROWS="11">
<TR>
<TD ROWSPAN="4">
<P/>
</TD>
<TH COLSPAN="4" VALIGN="BOTTOM">
<P>Number of children with adverse events</P>
</TH>
<TH COLSPAN="4" VALIGN="BOTTOM">
<P>Number of adverse events</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" VALIGN="TOP">
<P>
<LINK REF="STD-Zar-2007" TYPE="STUDY">Zar 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Madhi-2011" TYPE="STUDY">Madhi 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Gray-2014" TYPE="STUDY">Gray 2014</LINK>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Children not on ART</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Children on ART</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Children on ART</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Children on ART</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Isoniazid prophylaxis group</P>
<P>N = 91</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo group</P>
<P>N = 91</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Isoniazid prophylaxis group</P>
<P>N = 41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo group</P>
<P>N = 40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Isoniazid prophylaxis group</P>
<P>N = 273</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo group</P>
<P>N = 274</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Isoniazid prophylaxis group</P>
<P>N= 85</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo group</P>
<P>N = 82</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P>
<B>Clinical adverse events</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Peripheral neuropathy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Other clinical adverse events</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="9" VALIGN="TOP">
<P>
<B>Laboratory adverse events</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Haematological (neutropenia, thrombocytopenia, anaemia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Liver enzyme abnormalities</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Other laboratory adverse events</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: ART: antiretroviral therapy; N: number of participants.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-07-04 13:49:58 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-08-13 12:42:25 +0100" MODIFIED_BY="[Empty name]">Optimal information size calculations</TITLE>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcome</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Source</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Clinically important relative reduction</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Sample size required<SUP>1,2</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Active TB</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46/366 (13%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2990</P>
</TD>
</TR>
<TR>
<TD>
<P>Death</P>
</TD>
<TD>
<P>15/366 (4%)</P>
</TD>
<TD>
<P>
<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>
</P>
</TD>
<TD>
<P>50%</P>
</TD>
<TD>
<P>2282</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>We based all calculations on: 2-sided tests, with a ratio of 1:1, power of 0.8, and confidence level of 0.05.<BR/>
<SUP>2</SUP>We performed all calculations using: <A HREF="http://www.sealedenvelope.com/power/binary-superiority">sealedenvelope.com/power/binary-superiority</A>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-07-12 08:02:26 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-07-12 08:02:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral therapy (ART)</NAME>
<DICH_OUTCOME CHI2="0.8419667470870525" CI_END="1.1424927736155324" CI_START="0.5028674183460405" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7579725532940161" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.05785346179324567" LOG_CI_START="-0.2985465021617704" LOG_EFFECT_SIZE="-0.12034652018426235" METHOD="MH" MODIFIED="2017-06-05 07:36:01 +0100" MODIFIED_BY="Clare Dooley" NO="1" P_CHI2="0.6564010317863309" P_Q="1.0" P_Z="0.18561849258116522" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="366" WEIGHT="100.0" Z="1.3236524639808798">
<NAME>Active TB</NAME>
<GROUP_LABEL_1>Isoniazid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours isoniazid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2761039165178116" CI_START="0.525346670808346" EFFECT_SIZE="0.8187777135145556" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="38" LOG_CI_END="0.10588604157375762" LOG_CI_START="-0.27955401557956866" LOG_EFFECT_SIZE="-0.08683398700290554" MODIFIED="2017-03-17 07:30:50 +0000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.22640939753091793" STUDY_ID="STD-Madhi-2011" TOTAL_1="273" TOTAL_2="274" VAR="0.051261215290313224" WEIGHT="81.15864430363342">
<FOOTNOTE>Mahdi 2011: All children on co-trimoxazole, and 98.9% on ART; randomized to 10-20mg/kg INH per day versus placebo.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8128023572288077" CI_START="0.16763445958733117" EFFECT_SIZE="0.5512605042016807" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2583504572428426" LOG_CI_START="-0.7756367012765836" LOG_EFFECT_SIZE="-0.25864312201687045" MODIFIED="2017-03-17 07:30:50 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.6073691752332928" STUDY_ID="STD-Gray-2014" TOTAL_1="85" TOTAL_2="82" VAR="0.36889731502357037" WEIGHT="15.246717766480952">
<FOOTNOTE>Gray 2014: Number of children on co-trimoxazole not stated, 100% on ART; randomized to 8-12 mg/kg INH per day or thrice weekly versus placebo.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.823391074469541" CI_START="0.011779065398701277" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7651759564794982" LOG_CI_START="-1.928889166958849" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2017-03-17 07:30:50 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="1.582507189345124" STUDY_ID="STD-Zar-2007" TOTAL_1="13" TOTAL_2="10" VAR="2.504329004329004" WEIGHT="3.5946379298856264">
<FOOTNOTE>ZAR 2007: All children on cotrimoxazole, only 9% of those randomized were on ART at baseline; randomized to 8-12 mg/kg INH daily or thrice weekly versus placebo</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19044076831847814" CI_END="2.7223535827342773" CI_START="0.776695987757041" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4541117924581035" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.43494453124855775" LOG_CI_START="-0.10974893831073891" LOG_EFFECT_SIZE="0.1625977964689094" METHOD="MH" MODIFIED="2017-06-05 07:36:12 +0100" MODIFIED_BY="Clare Dooley" NO="2" P_CHI2="0.6625500305756734" P_Q="1.0" P_Z="0.24194167449937176" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="366" WEIGHT="100.0" Z="1.1701474053011152">
<NAME>Death</NAME>
<GROUP_LABEL_1>Isoniazid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours isoniazid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6675724036280086" CI_START="0.7401430867111856" EFFECT_SIZE="1.405128205128205" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.42611621593882226" LOG_CI_START="-0.13068431302308245" LOG_EFFECT_SIZE="0.14771595145786992" MODIFIED="2017-03-17 07:31:03 +0000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.32706738691929266" STUDY_ID="STD-Madhi-2011" TOTAL_1="273" TOTAL_2="274" VAR="0.10697307558621427" WEIGHT="96.7129976410612">
<FOOTNOTE>Mahdi 2011: All children on co-trimoxazole, and 98.9% on ART; randomized to 10-20mg/kg INH per day versus placebo.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-17 07:31:03 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Zar-2007" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>ZAR 2007: All children on cotrimoxazole, only 9% of those randomized were on ART at baseline; randomized to 8-12 mg/kg INH daily or thrice weekly versus placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="70.06850093533143" CI_START="0.11964070555564267" EFFECT_SIZE="2.895348837209302" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.845522826178066" LOG_CI_START="-0.9221210344737287" LOG_EFFECT_SIZE="0.4617008958521686" MODIFIED="2017-03-17 07:31:03 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="1.6257277038049263" STUDY_ID="STD-Gray-2014" TOTAL_1="85" TOTAL_2="82" VAR="2.642990566918838" WEIGHT="3.287002358938813">
<FOOTNOTE>Gray 2014: Number of children on co-trimoxazole not stated, 100% on ART; randomized to 8-12 mg/kg INH per day or thrice weekly versus placebo.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-07-12 10:53:58 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-07-09 17:10:23 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAr0AAALiCAYAAADU/G76AABnOUlEQVR42uzdD8QVef8//g9JkiSS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-07-02 12:08:18 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASsAAAGvCAIAAACM52QtAAARq0lEQVR42u3dv45dRRLH8ZGQEIED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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-07-02 12:08:29 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-07-12 10:53:48 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.1 Active TB, HIV-positive children on ART.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAAEACAMAAADiArLMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-07-12 10:53:58 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.2 Death, HIV-positive children on ART.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAAEACAMAAADiArLMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-07-09 18:21:34 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-07-09 18:21:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-07-09 18:21:34 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-07-09 18:20:34 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="7">
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>Search (#5 AND #6)</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>Search (infant[mh] OR infant[tiab] OR infants[tiab] OR infancy[tiab] OR toddler*[tiab] OR preterm*[tiab] OR prematur*[tiab] OR postmatur*[tiab] OR baby[tiab] OR babies[tiab] OR neonat*[tiab] OR newborn[tiab] OR preschool*[tiab] OR pre-school*[tiab] OR child[mh] OR child*[tiab] OR kindergar*[tiab] OR pupil*[tiab] OR schoolchild*[tiab] OR teen*[tiab] OR youth[tiab] OR youths[tiab] OR youngster*[tiab] OR young person*[tiab] OR young people[tiab] OR minors[mh] OR minors[tiab] OR puberty[mh] OR puberty[tiab] OR pubescen*[tiab] OR prepubescen*[tiab] OR paediatric*[tiab] OR pediatric*[tiab] OR peadiatric*[tiab] OR schools[mh:noexp] OR school*[tiab] OR kid[tiab] OR kids[tiab] OR boy*[tiab] OR girl*[tiab] OR creche*[tiab] OR highschool*[tiab] OR juvenil*[tiab] OR adolescent[mh] OR adolescen*[tiab] OR under ag*[tiab] OR underag*[tiab])</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>Search (#1 AND #2 AND #3 AND #4)</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>Search (chemoprevention[mh] OR chemoprevention[tiab] OR chemoprophylaxis[tiab] OR prophylaxis[tiab] OR antitubercular agents[mh] OR antitubercular agents[tiab] OR antitubercular drugs[tiab] OR antituberculosis drugs[tiab] OR tuberculostatic agents[tiab] OR preventive therapy[tiab])</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>Search (tuberculosis[mh] OR tuberculosis[tiab] OR tb[tiab] OR tuberculoses[tiab])</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp])</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-07-09 18:21:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2017-07-09 18:21:22 +0100" MODIFIED_BY="[Empty name]">Cochrane library search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-07-09 18:20:47 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="10">
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>#6 and #7 and #8 and #9, in Trials</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>[mh infant] or infant:ti,ab,kw or infants:ti,ab,kw or infancy:ti,ab,kw or toddler*:ti,ab,kw or preterm*:ti,ab,kw or prematur*:ti,ab,kw or postmatur*:ti,ab,kw or baby:ti,ab,kw or babies:ti,ab,kw or neonat*:ti,ab,kw or newborn:ti,ab,kw or preschool*:ti,ab,kw or "pre-school*":ti,ab,kw or [mh child] or child*:ti,ab,kw or kindergar*:ti,ab,kw or pupil*:ti,ab,kw or schoolchild*:ti,ab,kw or teen*:ti,ab,kw or youth:ti,ab,kw or youths:ti,ab,kw or youngster*:ti,ab,kw or (young next person*):ti,ab,kw or (young next people):ti,ab,kw or [mh minors] or minors:ti,ab,kw or [mh puberty] or puberty:ti,ab,kw or pubescen*:ti,ab,kw or prepubescen*:ti,ab,kw or paediatric*:ti,ab,kw or pediatric*:ti,ab,kw or peadiatric*:ti,ab,kw or [mh ^schools] or school*:ti,ab,kw or kid:ti,ab,kw or kids:ti,ab,kw or boy*:ti,ab,kw or girl*:ti,ab,kw or creche*:ti,ab,kw or highschool*:ti,ab,kw or juvenil*:ti,ab,kw or [mh adolescent] or adolescen*:ti,ab,kw or under ag*:ti,ab,kw or underag*:ti,ab,kw (Word variations have been searched)</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>[mh chemoprevention] or chemoprevention:ti,ab,kw or chemoprophylaxis:ti,ab,kw or prophylaxis:ti,ab,kw or [mh "antitubercular agents"] or (antitubercular agents):ti,ab,kw or (antitubercular drugs):ti,ab,kw or (antituberculosis drugs):ti,ab,kw or (tuberculostatic agents):ti,ab,kw or (preventive therapy):ti,ab,kw (Word variations have been searched)</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>[mh tuberculosis] or tuberculosis:ti,ab,kw or tuberculoses:ti,ab,kw or tb:ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Lymphoma, AIDS-Related] this term only</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunedeficiency virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (acquired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun* deficiency syndrome)</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [HIV] explode all trees</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [HIV Infections] explode all trees</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-07-09 18:21:11 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2017-07-09 18:21:11 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-07-09 18:20:41 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="12">
<TR>
<TD>
<P>
<B>#12 </B>
</P>
</TD>
<TD>
<P>#10 AND #11</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#11 </B>
</P>
</TD>
<TD>
<P>'infant'/exp OR infant:ab,ti OR infants:ab,ti OR infancy:ab,ti OR toddler*:ab,ti OR preterm*:ab,ti OR prematur*:ab,ti OR postmatur*:ab,ti OR baby:ab,ti OR babies:ab,ti OR neonat*:ab,ti OR newborn:ab,ti OR preschool*:ab,ti OR pre+school*:ab,ti OR 'child'/exp OR child*:ab,ti OR kindergar*:ab,ti OR pupil*:ab,ti OR schoolchild*:ab,ti OR teen*:ab,ti OR youth:ab,ti OR youths:ab,ti OR youngster*:ab,ti OR 'young person':ab,ti OR 'young persons':ab,ti OR 'young people':ab,ti OR 'minors'/exp OR minors:ab,ti OR 'puberty'/exp OR puberty:ab,ti OR pubescen*:ab,ti OR prepubescen*:ab,ti OR paediatric*:ab,ti OR pediatric*:ab,ti OR peadiatric*:ab,ti OR 'schools'/exp OR school*:ab,ti OR kid:ab,ti OR kids:ab,ti OR boy*:ab,ti OR girl*:ab,ti OR creche*:ab,ti OR highschool*:ab,ti OR 'juvenile'/exp OR juvenil*:ab,ti OR 'adolescent'/exp OR adolescen*:ab,ti OR (under NEXT/1 ag*):ab,ti OR underag*:ab,ti</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#10 </B>
</P>
</TD>
<TD>
<P>#1 AND #7 AND #8 AND #9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#9 </B>
</P>
</TD>
<TD>
<P>'chemoprevention'/de OR chemoprevention:ab,ti OR 'chemoprophylaxis'/de OR chemoprophylaxis:ab,ti OR prophylaxis:ab,ti OR (antitubercular NEXT/1 (agent* OR drug*)):ab,ti OR ('anti tubercular' NEXT/1 (agent* OR drug*)):ab,ti OR (antituberculosis NEXT/1 (agent* OR drug*)):ab,ti OR 'tuberculostatic agent'/de OR (tuberculostatic NEXT/1 agent*):ab,ti OR 'preventive therapy':ab,ti</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#8 </B>
</P>
</TD>
<TD>
<P>'tuberculosis'/exp OR tuberculosis:ab,ti OR tuberculoses:ab,ti OR tb:ab,ti</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#7 </B>
</P>
</TD>
<TD>
<P>#2 NOT #6</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#6 </B>
</P>
</TD>
<TD>
<P>#3 NOT #5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#5 </B>
</P>
</TD>
<TD>
<P>#3 AND #4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#4 </B>
</P>
</TD>
<TD>
<P>'human'/de OR 'normal human'/de OR 'human cell'/de</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#3 </B>
</P>
</TD>
<TD>
<P>'animal'/de OR 'animal experiment'/de OR 'invertebrate'/de OR 'animal tissue'/de OR 'animal cell'/de OR 'nonhuman'/de</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#2 </B>
</P>
</TD>
<TD>
<P>'randomized controlled trial'/de OR 'randomized controlled trial' OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR factorial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR 'crossover procedure'/de OR 'crossover procedure' OR 'double-blind procedure'/de OR 'double-blind procedure' OR 'single-blind procedure'/de OR 'single-blind procedure' OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*):ab,ti</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>#1 </B>
</P>
</TD>
<TD>
<P>'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus'/exp OR 'human immunodeficiency virus':ab,ti OR 'human immuno+deficiency virus':ab,ti OR 'human immunedeficiency virus':ab,ti OR 'human immune+deficiency virus':ab,ti OR hiv:ab,ti OR 'hiv-1':ab,ti OR 'hiv-2':ab,ti OR 'acquired immunodeficiency syndrome':ab,ti OR 'acquired immuno+deficiency syndrome':ab,ti OR 'acquired immunedeficiency syndrome':ab,ti OR 'acquired immune+deficiency syndrome':ab,ti</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_16810_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16810">
<ADDRESS>
<DEPARTMENT>Cochrane South Africa</DEPARTMENT>
<ORGANISATION>South African Medical Research Council</ORGANISATION>
<ADDRESS_1>PO Box 19070</ADDRESS_1>
<ADDRESS_2>Tygerberg</ADDRESS_2>
<CITY>Cape Town</CITY>
<ZIP>7505</ZIP>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 938 0256</PHONE_1>
<PHONE_2>+27 21 938 0438</PHONE_2>
<FAX_1>+27 21 938 0836</FAX_1>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study already included in previous version of the review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 new studies included&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;725 abstracts screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;719 records identified through database searching (2007-2017)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;6 records were identified through other sources (non-Cochrane review, clinicalTrials.gov, WHO ICTRP) (2007-2017)&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;717 abstracts excluded&lt;/p&gt;" WIDTH="100"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6 full-text articles excluded&lt;/p&gt;" WIDTH="180"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>